Harmony Biosciences Holdings Announces CEO Succession and Reaffirms 2026 Guidance
What happened
The Board of Directors appointed Peter Anastasiou, who is currently Sr. EVP and Chief Operating Officer, as President and Chief Executive Officer of Harmony Biosciences Holdings, Inc., effective January 1, 2027. Jeffrey M. Dayno, the current CEO, will retire from his role on December 31, 2026, and will serve as a non-executive advisor through 2027. The company reiterated its full-year 2026 WAKIX® net revenue guidance of $1.0 billion to $1.04 billion and stated it remains on track to report data from the BP-205 MAD study in Q4 2026.
From manilatimes.net
Why it matters
The succession plan maintains the company's stated financial outlook for 2026, with net revenue guidance remaining between $1.0 billion and $1.04 billion. The company also confirmed its timeline for reporting clinical trial data from the BP-205 study in the fourth quarter of 2026.
From manilatimes.net
Who's involved
- companyHarmony Biosciences Holdings, Inc., the company undergoing the leadership transition.
Keep exploring
The entities involved
-
company
legal entity representing an association of people, whether natural, legal or a mixture of both, with a specific objective
-
board of directors
group of people who jointly supervise the activities of an organization